LACE+ and MRS Score Readmission Rate Assessment

Comparing the Predictive Strength of the LACE+ Index With the MedWise Rise Score on Hospital Readmission Rates: a Non-inferiority Observational Study

A study to demonstrate that the LACE+ score in non-inferior to the medication risk score when predicting 30-day readmission post hospital discharge.

Study Overview

• Status: Terminated
• Conditions: Hospitalism
• Intervention / Treatment: Other: Pharmacist transition of care consultation

Detailed Description

The objective of this study is evaluate a program that provides transition of care services to a local Tucson hospital involving activities designed to reduce 30 day post hospital discharge readmission rates. The organization has had a fee for service contract with this hospital since 2017 to provide pharmacist delivered transition of care services. The organization collects internal tracking outcome data as part of the contract deliverable and is required to report it to the hospital once per month. The investigators look to assess LACE+ and medication risk scores to learn if there is an association with the 30 day post hospital discharge readmission rate post pharmacist intervention. The outcomes will not be generalizable and will be reported back to the hospital client to demonstrate value added.

• Study Type: Observational
• Enrollment (Actual): 100

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Tucson, Arizona, United States, 85701
      • Tabula Rasa HealthCare

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 88 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Information will be collected from an internal data collection excel used to provide monthly outcome intervention reports to the local Tucson hospital.

Description

Inclusion Criteria:

• Those referred to receive transition of care services between January 2018 to December 2019 and were discharged on 10 or more medications.

Exclusion Criteria:

• 89 years or older

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Retrospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Readmitted; Patients that were readmitted within 30 days post hospital discharge	Other: Pharmacist transition of care consultation; Pharmacist-delivered comprehensive medication review
Not readmitted; Patients that were not readmitted within 30 days post hospital discharge	Other: Pharmacist transition of care consultation; Pharmacist-delivered comprehensive medication review

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Readmission	Readmission within 30-days post hospital discharge	2018 - 2019

Collaborators and Investigators

• Sponsor: Tabula Rasa HealthCare
• Investigators: Principal Investigator: Jennifer Bingham, PharmD, Tabula Rasa HealthCare

Study record dates

Study Major Dates

• Study Start (Actual): July 7, 2020
• Primary Completion (Actual): March 1, 2021
• Study Completion (Actual): March 1, 2021

Study Registration Dates

• First Submitted: April 24, 2020
• First Submitted That Met QC Criteria: April 24, 2020
• First Posted (Actual): April 28, 2020

Study Record Updates

• Last Update Posted (Actual): March 17, 2022
• Last Update Submitted That Met QC Criteria: March 2, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: LACE; medication risk score
• Other Study ID Numbers: TRHC_RD_LACEMRS_2020

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No